Max Bayer is a Staff Writer at Biotech. He covers a range of topics including medicine and healthcare, finance, and the evolving landscape of cannabis and psychedelics, with a particular focus on biotech, business leaders, and startups. Max's work has been featured in notable publications such as Fierce Pharma and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Max Bayer's coverage primarily focuses on the healthcare and pharmaceutical industry, specifically on biotech, drug development, FDA approvals, and clinical trials. His articles often contain press releases and cite data from private sector announcements.
To effectively reach out to Max Bayer, consider providing pitches related to groundbreaking advancements in biotechnology or pharmaceuticals with a focus on new drug applications, significant leadership changes within prominent companies in the industry, as well as noteworthy partnerships or deals between key players. Additionally, offering insights supported by reliable data could enhance the appeal of your pitch.
Given that Max Bayer does not have a specific geographic focus mentioned but covers global developments within the healthcare and pharmaceutical sectors, ensure that your pitches reflect international relevance rather than being region-specific.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Arjun Goyal and Stefan Vitorovic, two of Vida Ventures' three co-founding managing directors, have exited the firm as it rejigs its leadership team seven years …
By: Max Bayer
A new psychedelic-focused startup incubator is debuting, backed by an investor behind some of the most prominent biotechs in the space. The main theme of the companies it wants to ...
With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is what they'll try and treat next …
By: Max Bayer
Advisors to the FDA had difficulty dissecting a small but concerning set of safety data from Moderna's pediatric RSV vaccine data, largely concluding that other …
By: Max Bayer
McKinsey has accepted a $650 million fine after admitting that it helped accelerate sales of Purdue Pharma's opioid products and misled the US government about …
By: Max Bayer
A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal hyperplasia, a condition marked …
By: Max Bayer
AstraZeneca said the FDA declined to fully approve its anticoagulant reversal drug Andexxa, less than a month after an advisory committee meeting at which the …
By: Max Bayer
Pfizer projects flat 2025 revenue, plans more cost cuts and R&D focus under CSO Chris Boshoff, while CEO Bourla addresses Trump meeting and maintains dividend commitment.
The FDA rejected Zealand Pharma's short bowel syndrome drug, and asked the company to run another trial before it reconsiders. The FDA told Zealand it …
By: Max Bayer, Alex Hoffman
→ Yuki Abe will step in to replace the late Toshinori Agatsuma on Jan. 1 as head of … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
(833) 317-6278 
